Customizable Platform Technology
Enables High Affinity Monoclonal
Isolated antibodies possess much greater drug binding and selectivity compared to previous efforts in the scientific literature
Pharmacokinetics of free drug
Substance of abuse distributes from blood to the brain, where it interacts with receptors to cause psychotropic and potentially dangerous effects.
Pharmacokinetics of drug-specific antibody
Our antibody therapy binds to the substance of abuse in the bloodstream, preventing it from getting into the brain and exerting its harmful and psychotropic effects.
Monoclonal antibodies sequester the substance of abuse in the bloodstream, preventing it from affecting the brain. The use of monoclonal antibodies allows for tight control of dosing as well as providing immediate protection after treatment. The monoclonal antibody is restricted to the blood stream, and thus not likely to have abuse potential of its own or to induce psychiatric side-effects common to other treatments for substance use disorders.
CMC & Tox
CSX-1004 is a human monoclonal antibody directed against fentanyl and fentanyl analogs. It is being developed as an IV infusion product that will offer immediate protection and last for at least 30 days. Phase 1 clinical trials of the CSX-1004 IV infusion are expected to commence in June 2023 to examine safety, pharmacokinetics and immunogenicity of CSX-1004 in healthy human subjects.